Who are Lactobacillus plantarum strain 299's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): lactobacillus LB, lactobacillus LS.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lactobacillus-plantarum-strain-299.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Lactobacillus plantarum strain 299 — Competitive Intelligence Brief

Lactobacillus plantarum strain 299 (Lactobacillus plantarum strain 299) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Live biotherapeutic product / Probiotic. Area: Oncology / Immunology.

phase 3 Live biotherapeutic product / Probiotic Oncology / Immunology Biologic Live · refreshed every 30 min

Target snapshot

Lactobacillus plantarum strain 299 (Lactobacillus plantarum strain 299) — Children's Oncology Group. Lactobacillus plantarum strain 299 is a probiotic bacterium that modulates the gut microbiome and intestinal barrier function to support immune homeostasis.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
Lactobacillus plantarum strain 299 TARGET	Lactobacillus plantarum strain 299	Children's Oncology Group	phase 3	Live biotherapeutic product / Probiotic
lactobacillus LB	lactobacillus LB	Hospital General de Mexico	marketed	Live biotherapeutic product / Probiotic
lactobacillus LS	lactobacillus LS	Ain Shams University	phase 3	Live biotherapeutic product / Probiotic

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Live biotherapeutic product / Probiotic class)

Ain Shams University · 1 drug in this class
Children's Oncology Group · 1 drug in this class
Hospital General de Mexico · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lactobacillus plantarum strain 299 — Competitive Intelligence Brief. https://druglandscape.com/ci/lactobacillus-plantarum-strain-299. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab